Neuropeptides
Volume 44, Issue 2 , Pages 145-154 , April 2010

Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors

References 

  1. AbdAlla S, Jarnagin K, Muller-Esterl W, Quitterer U. The N-terminal amino group of [Tyr8]bradykinin is bound adjacent to analogous amino acids of the human and rat B2 receptor. J. Biol. Chem. 1996;271:27382–27387
  2. Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur. J. Pharmacol. 2006;533:215–221
  3. Adomeit A, Graness A, Gross S, Seedorf K, Wetzker R, Liebmann C. Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation. Mol. Cell Biol. 1999;19:5289–5297
  4. Aktan F. INOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75:639–653
  5. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997;29:483–487
  6. Andreeva AV, Vaiskunaite R, Kutuzov MA, Profirovic J, Skidgel RA, Voyno-Yasenetskaya T. Novel mechanisms of g protein-dependent regulation of endothelial nitric-oxide synthase. Mol. Pharmacol. 2006;69:975–982
  7. Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, et al. The American–European consensus conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1998;157:1332–1347
  8. Austin CE, Faussner A, Robinson HE, Chakravarty S, Kyle DJ, Bathon JM, et al. Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J. Biol. Chem. 1997;272:11420–11425
  9. Bachetti T, Comini L, Curello S, Bastianon D, Palmieri M, Bresciani G, et al. Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. J. Mol. Cell Cardiol. 2004;37:939–945
  10. Bernier SG, Haldar S, Michel T. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J. Biol. Chem. 2000;275:30707–30715
  11. Berthiaume N, Hess F, Chen A, Regoli D, D’Orleans-Juste P. Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur. J. Pharmacol. 1997;333:55–61
  12. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992;44:1–80
  13. Blaukat A. Structure and signalling pathways of kinin receptors. Andrologia. 2003;35:17–23
  14. Blaukat A, Barac A, Cross MJ, Offermanns S, Dikic I. G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals. Mol. Cell Biol. 2000;20:6837–6848
  15. Blaukat A, Pizard A, Rajerison RM, Alhenc-Gelas F, Muller-Esterl W, Dikic I. Activation of mitogen-activated protein kinase by the bradykinin B2 receptor is independent of receptor phosphorylation and phosphorylation-triggered internalization. FEBS Lett. 1999;451:337–341
  16. Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases. Bone. 2008;43:72–83
  17. Brovkovych V, Gao X-P, Ong E, Brovkovych S, Brennan M-L, Su X, et al. Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2008;295:L96–L103
  18. Brovkovych, V., Zhang, Y., Brovkovych, S., Minshall, R.D., Skidgel, R.A., 2009. A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase. J. Cell. Mol. Med. doi:10.1111/j.1582-4934.2009.00992.x.
  19. Bujalska M, Makulska-Nowak H. Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model. Neuro. Endocrinol. Lett. 2009;30:144–152
  20. Butt E, Bernhardt M, Smolenski A, Kotsonis P, Frohlich LG, Sickmann A, et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 2000;275:5179–5187
  21. Cale JM, Bird IM. Inhibition of MEK/ERK1/2 signalling alters endothelial nitric oxide synthase activity in an agonist-dependent manner. Biochem. J. 2006;398:279–288
  22. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007;49:590–596
  23. Campos MM, Leal PC, Yunes RA, Calixto JB. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol. Sci. 2006;27:646–651
  24. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pilz B, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J. 2007;21:1689–1698
  25. Chen BC, Lin LL, Lin WW. Protein kinase C epsilon-dependent pathway of extracellular signal-regulated protein kinase activation by P2Y1 and P2Y2 purinoceptors that activate cytosolic phospholipase A2 in endothelial cells. Eur. J .Pharmacol. 1999;373:101–110
  26. Chen DB, Bird IM, Zheng J, Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology. 2004;145:113–125
  27. Chen Z, Deddish PA, Minshall RD, Becker RP, Erdos EG, Tan F. Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J. 2006;20:2261–2270
  28. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443:285–289
  29. Christopher J, Velarde V, Jaffa AA. Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation. Hypertension. 2001;38:602–605
  30. de Campos RO, Alves RV, Ferreira J, Kyle DJ, Chakravarty S, Mavunkel BJ, et al. Oral antinociception and oedema inhibition produced by NPC 18884, a non-peptidic bradykinin B2 receptor antagonist. Naunyn Schmiedebergs Arch. Pharmacol. 1999;360:278–286
  31. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature. 1996;383:547–550
  32. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605
  33. Donnini S, Solito R, Giachetti A, Granger HJ, Ziche M, Morbidelli L. Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J. Pharmacol. Exp. Ther. 2006;319:515–522
  34. Dudzinski DM, Igarashi J, Greif D, Michel TM. The regulation and pharmacology of endothelial nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 2006;46:235–276
  35. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc. Res. 2007;75:247–260
  36. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, et al. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension. 2008;51:1352–1357
  37. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation. 1999;100:2359–2365
  38. Erwin PA, Lin AJ, Golan DE, Michel T. Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 2005;280:19888–19894
  39. Feletou M, Jamonneau I, Germain M, Thurieau C, Fauchere JL, Villa P, et al. Bradykinin B2 receptor involvement in rabbit and murine models of septic shock. J. Cardiovasc. Pharmacol. 1996;27:500–507
  40. Feng DM, DiPardo RM, Wai JM, Chang RK, Di Marco CN, Murphy KL, et al. A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity. Bioorgan. Med. Chem. Lett. 2008;18:682–687
  41. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 2001;88:E68–E75
  42. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 2002;90:866–873
  43. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem. Pharmacol. 1995;50:1321–1332
  44. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597–601
  45. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough?. J. Pharmacol. Exp. Ther. 2001;299:818–824
  46. Fulton D, Ruan L, Sood SG, Li C, Zhang Q, Venema RC. Agonist-stimulated endothelial nitric oxide synthase activation and vascular relaxation. Role of eNOS phosphorylation at Tyr83. Circ. Res. 2008;102:497–504
  47. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem. 1997;272:25437–25440
  48. Ghalayini IF. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. Int. J. Impot. Res. 2004;16:459–469
  49. Gohla A, Offermanns S, Wilkie TM, Schultz G. Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J. Biol. Chem. 1999;274:17901–17907
  50. Goldspink PH, Montgomery DE, Walker LA, Urboniene D, McKinney RD, Geenen DL, et al. Protein kinase Cepsilon overexpression alters myofilament properties and composition during the progression of heart failure. Circ. Res. 2004;95:424–432
  51. Golser R, Gorren AC, Leber A, Andrew P, Habisch HJ, Werner ER, et al. Interaction of endothelial and neuronal nitric-oxide synthases with the bradykinin B2 receptor. Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation. J. Biol. Chem. 2000;275:5291–5296
  52. Gross SS, Kilbourn RG, Griffith OW. NO in septic shock: good, bad or ugly? Learning from iNOS knockouts. Trends Microbiol. 1996;4:47–49
  53. Guan ZW, Iyanagi T. Electron transfer is activated by calmodulin in the flavin domain of human neuronal nitric oxide synthase. Arch. Biochem. Biophys. 2003;412:65–76
  54. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem. 2001;276:16587–16591
  55. Heitsch H. Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect. 2000;13:213–225
  56. Herzig MC, Leeb-Lundberg LM. The agonist binding site on the bovine bradykinin B2 receptor is adjacent to a sulfhydryl and is differentiated from the antagonist binding site by chemical cross-linking. J. Biol. Chem. 1995;270:20591–20598
  57. Herzig MC, Nash NR, Connolly M, Kyle DJ, Leeb-Lundberg LM. The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys20 and Cys277 in the receptor. J. Biol. Chem. 1996;271:29746–29751
  58. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Brit. J. Pharmacol. 1991;102:769–773
  59. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 1999;34:879–886
  60. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdös EG. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: Signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol. Pharmacol. 2004;66:1310–1316
  61. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J. Biol. Chem. 2002;277:16847–16852
  62. Issandou M, Darbon JM. Des-Arg9 bradykinin modulates DNA synthesis, phospholipase C, and protein kinase C in cultured mesangial cells. Distinction from effects of bradykinin. J. Biol. Chem. 1991;266:21037–21043
  63. Ju H, Venema VJ, Marrero MB, Venema RC. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J. Biol. Chem. 1998;273:24025–24029
  64. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 1997;272:18522–18525
  65. Kim JH, Jain D, Tliba O, Yang B, Jester WF, Panettieri RA, et al. TGF-beta potentiates airway smooth muscle responsiveness to bradykinin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005;289:L511–L520
  66. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 2004;500:255–266
  67. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem. J. 1994;298(Pt 2):249–258
  68. Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation. 1995;2:235–244
  69. Kuhr, F.K., Zhang, Y., Brovkovych, V., Skidgel, R.A., 2009. Beta-arrestin 2 is required for B1 receptor-dependent post-translational activation of inducible nitric oxide synthase. Submitted for publication.
  70. Labonte J, Brochu I, Honore JC, D’Orleans-Juste P. Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Brit. J. Pharmacol. 2001;132:934–940
  71. Lamb ME, De Weerd WF, Leeb-Lundberg LM. Agonist-promoted trafficking of human bradykinin receptors: arrestin- and dynamin-independent sequestration of the B2 receptor and bradykinin in HEK293 cells. Biochem. J. 2001;355:741–750
  72. Lamb ME, Zhang C, Shea T, Kyle DJ, Leeb-Lundberg LM. Human B1 and B2 bradykinin receptors and their agonists target caveolae-related lipid rafts to different degrees in HEK293 cells. Biochemistry. 2002;41:14340–14347
  73. Leeb-Lundberg LM, Kang DS, Lamb ME, Fathy DB. The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. Roles of residues in the fourth intracellular and third transmembrane domains. J. Biol. Chem. 2001;276:8785–8792
  74. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005;57:27–77
  75. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by {beta}-arrestins. Science. 2005;308:512–517
  76. Leung PC, Cheng KT, Liu C, Cheung WT, Kwan HY, Lau KL, et al. Mechanism of non-capacitative Ca2+ influx in response to bradykinin in vascular endothelial cells. J. Vasc. Res. 2006;43:367–376
  77. Liao JK, Homcy CJ. The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor. J. Clin. Invest. 1993;92:2168–2172
  78. Liebmann C, Graness A, Ludwig B, Adomeit A, Boehmer A, Boehmer FD, et al. Dual bradykinin B2 receptor signalling in A431 human epidermoid carcinoma cells: activation of protein kinase C is counteracted by a GS-mediated stimulation of the cyclic AMP pathway. Biochem. J. 1996;313(Pt 1):109–118
  79. Liu J, Garcia-Cardena G, Sessa WC. Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or −26, argues against depalmitoylation-induced translocation of the enzyme. Biochemistry. 1995;34:12333–12340
  80. Lowry, J., Brovkovych, V., Skidgel, R.A., 2009. Unpublished.
  81. Luckhoff A, Pohl U, Mulsch A, Busse R. Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Brit. J. Pharmacol. 1988;95:189–196
  82. Luhrs H, Papadopoulos T, Schmidt HH, Menzel T. Type I nitric oxide synthase in the human lung is predominantly expressed in capillary endothelial cells. Respir. Physiol. 2002;129:367–374
  83. Luksha L, Agewall S, Kublickiene K. Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis. 2009;202:330–344
  84. Lung CC, Jagels MA, Daffern PJ, Tan EM, Zuraw BL. Induction of human B2 bradykinin receptor mRNA and membrane receptors by IFNgamma. Immunopharmacology. 1998;39:243–253
  85. Ma QP, Heavens R. Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats. Neuroreport. 2001;12:2311–2314
  86. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol. Rev. 1998;50:357–386
  87. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, et al. Kinin receptors: functional aspects. Int. Immunopharmacol. 2002;2:1729–1739
  88. Masters BS, McMillan K, Sheta EA, Nishimura JS, Roman LJ, Martasek P. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates l-arginine to produce NO. As a cellular signal. FASEB J. 1996;10:552–558
  89. Matsuda H, Iyanagi T. Calmodulin activates intramolecular electron transfer between the two flavins of neuronal nitric oxide synthase flavin domain. Biochim. Biophys. Acta. 1999;1473:345–355
  90. McClintock DE, Ware LB, Eisner MD, Wickersham N, Thompson BT, Matthay MA The National Heart, L.a.B.I.A.N. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am. J. Respir. Crit. Care Med. 2007;175:256–262
  91. McLean PG, Perretti M, Ahluwalia A. Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9 bradykinin-induced coronary vasodilation. Brit. J. Pharmacol. 1999;128:275–282
  92. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. Circulation. 2004;110:3281–3288
  93. Merino, V.F., Todiras, M., Campos, L.A., Saul, V., Popova, E., Baltatu, O.C., Pesquero, J.B., Bader, M., 2008. Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J. Mol. Med.
  94. Michel JB, Feron O, Sase K, Prabhakar P, Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J. Biol. Chem. 1997;272:25907–25912
  95. Michel T, Li GK, Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 1993;90:6252–6256
  96. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 1999;9:845–848
  97. Michell BJ, Harris MB, Chen ZP, Ju H, Venema VJ, Blackstone MA, et al. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J. Biol. Chem. 2002;277:42344–42351
  98. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991;43:109–142
  99. Morgan-Boyd R, Stewart JM, Vavrek RJ, Hassid A. Effects of bradykinin and angiotensin II on intracellular Ca2+ dynamics in endothelial cells. Am. J. Physiol. 1987;253:C588–C598
  100. Nardone J, Hogan PG. Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding. Proc. Natl. Acad. Sci. USA. 1994;91:4417–4421
  101. Newton R, Eddleston J, Haddadel B, Hawisa S, Mak J, Lim S, et al. Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone. Eur. J. Pharmacol. 2002;441:193–202
  102. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J. Biol. Chem. 2003;278:219–225
  103. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 1999;43:509–520
  104. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA, Walther T, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA. 2000;97:8140–8145
  105. Pesquero JB, Bader M. Genetically altered animal models in the kallikrein-kinin system. Biol. Chem. 2006;387:119–126
  106. Pietrovski EF, Otuki MF, Regoli D, Bader M, Pesquero JB, Cabrini DA, et al. The non-peptide kinin receptor antagonists FR 173657 and SSR 240612: preclinical evidence for the treatment of skin inflammation. Regul. Pept. 2009;152:67–72
  107. Prabhakar P, Cheng V, Michel T. A chimeric transmembrane domain directs endothelial nitric-oxide synthase palmitoylation and targeting to plasmalemmal caveolae. J. Biol. Chem. 2000;275:19416–19421
  108. Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J. Cell. Physiol. 2002;193:275–286
  109. Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, Malik AB. Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005;289:L371–L381
  110. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980;32:1–46
  111. Regoli D, Jukic D, Gobeil F, Rhaleb NE. Receptors for bradykinin and related kinins: a critical analysis. Can. J. Physiol. Pharmacol. 1993;71:556–567
  112. Reverter D, Maskos K, Tan F, Skidgel RA, Bode W. Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity. J. Mol. Biol. 2004;338:257–269
  113. Robinson LJ, Michel T. Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc. Natl. Acad. Sci. USA. 1995;92:11776–11780
  114. Roman LJ, Masters BS. Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements. J. Biol. Chem. 2006;281:23111–23118
  115. Rosenkranz B, Bork K, Frank J, Kreuz W, Dong L, Knolle J. Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema. Clin. Pharmacol. Ther. 2005;77:P14
  116. Sabatini RA, Guimaraes PB, Fernandes L, Reis FC, Bersanetti PA, Mori MA, et al. ACE activity is modulated by kinin B2 receptor. Hypertension. 2008;51:689–695
  117. Sakamoto T, Sun J, Barnes PJ, Chung KF. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. Eur. J. Pharmacol. 1994;251:137–142
  118. Samadfam R, Teixeira C, Bkaily G, Sirois P, de Brum-Fernandes A, D’Orleans-Juste P. Contribution of B(2) receptors for bradykinin in arthus reaction-induced plasma extravasation in wild-type or B(2) transgenic knockout mice. Brit. J. Pharmacol. 2000;129:1732–1738
  119. Schilling WP, Rajan L, Strobl-Jager E. Characterization of the bradykinin-stimulated calcium influx pathway of cultured vascular endothelial cells. Saturability, selectivity, and kinetics. J. Biol. Chem. 1989;264:12838–12848
  120. Schmidt K, Gibraeil HD, Mayer B. Lack of involvement of extracellular signal-regulated kinase (ERK) in the agonist-induced endothelial nitric oxide synthesis. Biochem. Pharmacol. 2002;63:1137–1142
  121. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nature Med. 2009;15:788–793
  122. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 2002;64:749–774
  123. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, et al. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 1996;271:6518–6522
  124. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 1996;93:13176–13181
  125. Shughrue PJ, Ky B, Austin CP. Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study. J. Comput. Neurol. 2003;465:372–384
  126. Sittipunt C, Steinberg KP, Ruzinski JT, Myles C, Zhu SHA, Goodman RB, et al. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2001;163:503–510
  127. Skidgel RA. Proliferation of regulatory mechanisms for eNOS: an emerging role for the cytoskeleton. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002;282:L1179–L1182
  128. Skidgel RA, Erdös EG. Cellular carboxypeptidases. Immunol. Rev. 1998;161:129–141
  129. Skidgel RA, Erdös EG. Enzymatic breakdown of bradykinin. In:  Said SI editors. Pro-inflammatory and Anti-inflammatory Peptides. New York: Marcel Dekker; 1998;p. 459–476
  130. Skidgel RA, Stanisavljevic S, Erdos EG. Kinin- and angiotensin-converting enzyme (ACE) inhibitor-mediated nitric oxide production in endothelial cells. Biol. Chem. 2006;387:159–165
  131. Smith JA, Webb C, Holford J, Burgess GM. Signal transduction pathways for B1 and B2 bradykinin receptors in bovine pulmonary artery endothelial cells. Mol. Pharmacol. 1995;47:525–534
  132. Stanisavljevic S, Ignjatovic T, Deddish PA, Brovkovych V, Zhang K, Erdos EG, et al. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J. Pharmacol. Exp. Ther. 2006;316:1153–1158
  133. Stuehr DJ. Sructure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 1997;37:339–359
  134. Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm. Pharmacol. Ther. 2002;15:83–95
  135. Tirapelli CR, Bonaventura D, de Oliveira AM. Functional characterization of the mechanisms underlying bradykinin-induced relaxation in the isolated rat carotid artery. Life Sci. 2007;80:1799–1805
  136. Tropea MM, Gummelt D, Herzig MS, Leeb-Lundberg LM. B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by des-Arg9-bradykinin and bradykinin. J. Pharmacol. Exp. Ther. 1993;264:930–937
  137. Tsutsui M, Onoue H, Iida Y, Smith L, O’Brien T, Katusic ZS. B(1) and B(2) bradykinin receptors on adventitial fibroblasts of cerebral arteries are coupled to recombinant eNOS. Am. J. Physiol. Heart Circ. Physiol. 2000;278:H367–H372
  138. Velarde V, Ullian ME, Morinelli TA, Mayfield RK, Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am. J. Physiol. 1999;277:C253–C261
  139. Venema RC. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int. Immunopharmacol. 2002;2:1755–1762
  140. Voyno-Yasenetskaya TA, Tkachuk VA, Cheknyova EG, Panchenko MP, Grigorian GY, Vavrek RJ, et al. Guanine nucleotide-dependent, pertussis toxin-insensitive regulation of phosphoinositide turnover by bradykinin in bovine pulmonary artery endothelial cells. FASEB J. 1989;3:44–51
  141. Walker, K., Perkins, M., Dray, A., 1995. Kinins and kinin receptors in the nervous system. Neurochem. Int. 26, 1–16 (discussion 17–26).
  142. Wang PH, Campanholle G, Cenedeze MA, Feitoza CQ, Goncalves GM, Landgraf RG, et al. Bradykinin B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury. PLoS ONE. 2008;3:e3050
  143. Whalley ET, Solomon JA, Modafferi DM, Bonham KA, Cheronis JC. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions. 1992;38(Pt 3):413–420
  144. Wiemer G, Wirth K. Production of cyclic GMP via activation of B1 and B2 kinin receptors in cultured bovine aortic endothelial cells. J. Pharmacol. Exp. Ther. 1992;262:729–733
  145. Wink DA, Miranda KM, Espey MG, Pluta RM, Hewett SJ, Colton C, et al. Mechanisms of the antioxidant effects of nitric oxide. Antioxid. Redox. Signal. 2001;3:203–213
  146. Wotherspoon G, Winter J. Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci. Lett. 2000;294:175–178
  147. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang JJ, Bader M, et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp. Physiol. 2009;94:322–329
  148. Yang X, Taylor L, Polgar P. Effect of the G-protein, G alpha(i2), and G alpha(i3) subunit knockdown on bradykinin-induced signal transduction in rat-1 cells. Mol. Cell. Biol. Res. Commun. 1999;1:227–236
  149. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ. Res. 2001;88:1072–1079
  150. Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997;30:735–740
  151. Zhang X, Tan F, Zhang Y, Skidgel RA. Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists. J. Biol. Chem. 2008;283:7994–8004
  152. Zhang Y, Brovkovych V, Brovkovych S, Tan F, Lee BS, Sharma T, et al. Dynamic receptor-dependent activation of inducible nitric-oxide synthase by ERK-mediated phosphorylation of Ser745. J. Biol. Chem. 2007;282:32453–32461
  153. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide. 2009;20:223–230
  154. Zhu SHA, Ware LB, Geiser T, Matthay MA, Matalon S. Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury. Am. J. Respir. Crit. Care Med. 2001;163:166–172

PII: S0143-4179(09)00143-7

doi: 10.1016/j.npep.2009.12.004

Neuropeptides
Volume 44, Issue 2 , Pages 145-154 , April 2010

Article Tools

* Image Usage & Resolution